Hasan ERDEM, Süleyman ÇETİNKÜNAR, Mehmet AZİRET, Recep AKTİMUR, Sabri ÖZDAŞ, Fahri TETİŞİR, Banu YÜREKLİ

Effects of Intragastric Balloon on Body Mass Index, Lipid Profile and Blood Glucose Regulation: A Prospective Study

Amaç: Obezite giderek artan bir halk sağlığı ve sosyoe- konomik sorun olmaya devam etmektedir. Sağlıklı bes- lenme ve fiziksel aktivite de dâhil olmak üzere yaşam tar- zı değişiklikleri başarılı kilo kaybı için ilk basamak tedavi şekli olarak kabul görülmektedir. Gastrik balon kilo kaybı için etkili, geri dönüşümlü ve cerrahi olmayan bir yöntem- dir. Çalışmanın amacı, obez hastalarda intragastrik balo- nun kilo kaybı, lipit profili ve kan şekeri düzenlenmesine etkilerini araştırmaktır. Yöntemler: Bu çalışmada hastaların 35,2 ± 9,6 yaş orta- laması ile 75 ardışık mide balonu hastası (55 Bayan, 20 Erkek) çalışmaya dâhil edildi. Çalışma prospektif olarak planlandı ve hava-dolu mide balonu kontrolleri ayaktan poliklinikte yapıldı. Bu çalışmada, hastaların uygulama öncesi vücut kitle indeksi, HbA1c ve lipid profilleri gibi pe- riferik kan parametreleri, kaydedilerek müdahale sonrası değerleri ile karşılaştırıldı. Bulgular: Mide balonu uygulaması için medyan müdaha- le süresi 13 dakika (8-19) idi. Medyan 186 gün (180-211) izlem süresinden sonra, BMI, önemli ölçüde 41,6 ± 6,7 den 34,9 ± 6,4e azalma tespit edildi (p

İntragastrik Balonun Vücut Kitle İndeksi, Lipit Profili ve Kan Şekeri Regülasyonu Üzerine Etkileri: Prospektif Çalışma

Objective: Obesity remains an increasing public health and socioeconomic problem. Life style changes including healthy diet and physical activity are the first-line therapy for successful weight loss. The intragastric balloon has been considered as an effective and reversible, non-sur- gical method for weight loss. In this study, we aimed to investigate the effects of Intragastric balloon on weight loss, lipid profiles and blood glucose regulation in obese patients Methods: 75 consecutive Intragastric balloon patients (55 Female, 20 Male) with a mean age of 35.2±9.6 years were included in this study. The study was conducted prospectively and an air-filled intragastric balloon was introduced in ambulatory settings. In this study, patients pre-intervention body mass index, peripheral blood pa- rameters such as HbA1c, lipid profiles were recorded and compared with post-intervention values. Results: The median intervention time for intragastric balloon application was 13 min (8-19). After follow-up period of median 186 days (180-211), BMI was reduced significantly, 41.6±6.7 vs. 34.9±6.4 kg/m2 (p<0.001). The median excess weight loss was found to be 33.2% (14- 81.1). There is no statistically significant difference be- tween pre-intervention and post-intervention valuables in terms of low-density lipoprotein, high-density lipoprotein, cholesterol and triglycerides levels (p>0.05). On the other hand, only pre and post-intervention HbA1c level was to be statistically significant (p=0.001) Conclusion: There was significant change in BMI and HbA1c level with the intervention of intragastric balloon after follow-up period. For long-term benefit of balloon, further studies are needed.

Tam Metin

Kaynakça

1. Satman I, Omer B, Tutuncu Y, et al; TURDEP-II Study Group. Twelve-year trends in the prevalence and risk fac- tors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28:169-180. 2. WHO. Obesity: preventing and managing the global epi- demic. Report of a WHO consultation on obesity. Geneva: World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253. 3. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes Res 1998;6:464. 4. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12:1197-211. 5. Waseem T, Mogensen KM, Lautz DB, et al. Pathophysiology of obesity: why surgery remains the most effective treat- ment. Obes Surg 2007;17:1389-1398. 6. Vrabie CD, Cojocaru M, Waller M, et al. The main histopath- ological gastric lesions in obese patients who underwent sleeve gastrectomy. Dicle Med J 2010;37:97-103. 7. Doldi SB, Micheletto G, Di Prisco F, et al. Intragastric bal- loon in obese patients. Obes Surg 2000;10:578-581. 8. Buzga M, Evzen M, Pavel K, Tomas K, Vladislava Z, Pav- el Z, et al. Effects of the intragastric balloon Medsil® on Weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obes Surg 2014;24:909-915. 9. Genco A, Bruni T, Doldi SB, et al. Bioenterics intragastric Balloon: the Italian experience with 2515 patients. Obes Surg 2005;15:1161-1164. 10. Saruç M, Böler D, Karaarslan M, et al. Intragastric bal- loon treatment of obesity must be combined with bariat- ric surgery: a pilot study in Turkey. Turk J Gastroenterol 2010;21:333-337. 11. Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: What happens 5 years thereafter? Obes Surg 2012;22:896-903. 12. Sekino Y, Imajo K, Sakai E, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese pa- tients. Intern Med 2011;50:2449-2455. 13. Konopko-Zubrzycka M, Baniukiewicz A, Wroblewski E, et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obe- sity. J Clin Endocrinol Metab 2009;94:1644-1649. 14. Crea N, Pata G, Casa DD, et al. Improvement of Metabolic Syndrome following intragastric balloon: 1 year Follow-up Analysis. Obes Surg 2009;19:1084-1088. 15. Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the bioenterics intragastric balloon on weight, insulin resis- tance and liver steatosis in obese patients. Gastrointest En- dosc 2010;71:927-933. 16. Fuller NR, Pearson S, Lau NS, et al. An Intragastric Bal- loon in the Treatment Of Obese Individuals With Metabolic Syndrome: A Randomized Controlled Study. Obesity (Sil- ver Spring) 2013;21:1561-1570. 17. Yasawy MI, Al-Quorain AA, Hussameddin AM. Obe- sity and gastric balloon. J Family Community Med 2014;21:196-199.